CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

larotrectinib

Last Updated: November 16, 2020
Result type: Reports
Project Number: PC0221-000
Product Line: Reimbursement Review

Generic Name: larotrectinib

Brand Name: Vitrakvi

Manufacturer: Bayer Inc.

Therapeutic Area: Solid tumours with NTRK gene fusion

Indications: For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult and pediatric patients with solid tumours that: have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and, have no satisfactory treatment options.

Submission Type: Resubmission

Tumour Type: Other

NOC Status at Filing: Post NOC

Project Status: Received

Companion Diagnostics: No

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openOctober 16, 2020
Call for patient/clinician input closedDecember 04, 2020
Submission receivedNovember 16, 2020
Submission accepted-
Submit Feedback